Literature DB >> 34239289

Vitamin D in mild cognitive impairment and Alzheimer's disease. A study in older Greek adults.

E Mavraki1, P Ioannidis2, G Tripsianis3, T Gioka4, M Kolousi4, K Vadikolias1.   

Abstract

BACKGROUND: In recent years, accumulating evidence has linked vitamin D deficiency to cognitive dysfunction and dementia. This study aimed at determining the relevance of serum 25-hydroxyvitamin D concentrations in mild cognitive impairment (MCI) and Alzheimer's disease (AD) in older Greek adults. It also examined whether the vitamin D level could be considered a predisposing factor for conversion from MCI to AD.
METHODS: The study enrolled 350 subjects aged 65 years and over, allocated into three groups consisting of 103 healthy subjects (HS), 109 individuals with MCI, and 138 patients with AD, respectively. Serum 25-hydroxyvitamin D [25(OH)D] concentrations, measured in ng/ml, were determined by electrochemiluminescence, and we used the Mini-Mental State Examination (MMSE) and the Cambridge Cognition Examination (CAMGOG) to evaluate the subjects' cognitive status. One follow-up examination was performed for the MCI patients 30 months ± three months after the initial evaluation.
RESULTS: Compared to HS, serum 25(OH)D levels were significantly decreased in individuals with MCI (p =0.012) and patients with AD (p <0.001). Moreover, serum 25(OH)D concentrations were significantly decreased in patients with AD compared to individuals with MCI (p =0.003) and also significantly lower in individuals with MCI who progressed to AD compared to those who remained MCI (p =0.028). After adjusting for confounders, multivariate analysis revealed that an increase of vitamin D concentration by one ng/mL reduces the risk of MCI by 4 % (OR =0.96, 95 % CI =0.92-0.99, p =0.006), the risk of AD by 8 % (OR =0.92, 95 % CI =0.89-0.95, p <0.001), and in an individual with MCI reduces the risk of conversion to AD by 10 % (OR =0.90, 95 % CI =0.83-0.96, p =0.003).
CONCLUSIONS: The present study reveals that serum vitamin D levels are significantly decreased in subjects with MCI and patients with AD compared to HS. Additionally, individuals with MCI who progressed to AD presented significantly lower vitamin D levels than those who remained MCI. These results suggest that preserving adequate vitamin D status in older adults could delay or prevent cognitive decline. HIPPOKRATIA 2020, 24(3): 120-126. Copyright 2020, Hippokratio General Hospital of Thessaloniki.

Entities:  

Keywords:  Alzheimer’s disease; Vitamin D; mild cognitive impairment; progression

Year:  2020        PMID: 34239289      PMCID: PMC8256783     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  4 in total

1.  Association of vitamin D receptor gene TaqI polymorphism with Alzheimer's disease in a Southeastern European Caucasian population.

Authors:  Efthimios Dimitrakis; Martha-Spyridoula Katsarou; Maria Lagiou; Vasiliki Papastefanopoulou; Evangelia Stanitsa; Demetrios A Spandidos; Aristidis Tsatsakis; Socratis Papageorgiou; Paraskevi Moutsatsou; Katerina Antoniou; Christos Kroupis; Nikolaos Drakoulis
Journal:  Exp Ther Med       Date:  2022-03-22       Impact factor: 2.447

2.  Plasma Lipidomics Approach in Early and Specific Alzheimer's Disease Diagnosis.

Authors:  Carmen Peña-Bautista; Lourdes Álvarez-Sánchez; Marta Roca; Lorena García-Vallés; Miguel Baquero; Consuelo Cháfer-Pericás
Journal:  J Clin Med       Date:  2022-08-27       Impact factor: 4.964

Review 3.  Plants, Plants, and More Plants: Plant-Derived Nutrients and Their Protective Roles in Cognitive Function, Alzheimer's Disease, and Other Dementias.

Authors:  Helen Ding; Allison B Reiss; Aaron Pinkhasov; Lora J Kasselman
Journal:  Medicina (Kaunas)       Date:  2022-07-30       Impact factor: 2.948

Review 4.  Serum Vitamin D as a Biomarker in Autoimmune, Psychiatric and Neurodegenerative Diseases.

Authors:  Giulia Bivona; Caterina Maria Gambino; Bruna Lo Sasso; Concetta Scazzone; Rosaria Vincenza Giglio; Luisa Agnello; Marcello Ciaccio
Journal:  Diagnostics (Basel)       Date:  2022-01-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.